血管新生是创面愈合的基础，血管新生还参与了肿瘤生长，风湿病，缺血性心脏病等多种疾病的发生和发展，但机制不清。项目组前期研究结果显示，CFs能够抑制血管新生，并减缓创面愈合速率。体外CFs与VECs共培养后，CFs内IL-18和VECs内DARC表达明显增高，在CFs采用IL-18 RNAi可下调VECs内DARC的表达。鉴于DARC具有抑制血管新生的作用，项目组提出如下科学假设：CFs通过IL-18调控DARC进而抑制血管新生。为验证这一假设，项目组构建IL-18过表达和抑制腺病毒，采用免疫荧光、Western-blot、Realtime-PCR、流式细胞仪检测等方法，明确CFs内IL-18对VECs内DARC的调控作用及其信号转导机制，并在体内进行进一步的验证。本项目将进一步揭示CFs对血管新生的调控机制，有望为外科学创面的治疗以及血管新生相关疾病的治疗提供新的药物作用靶点和思路。

Angiogenesis is the basis of wound healing, and it is involved in a variety of diseases such as tumor growth, rheumatism, and ischemic heart disease occurrence and development, but the mechanism is not clear. The early stage of the project research shows that CFs can inhibit angiogenesis, and slow wound healing rate. After trained CFs and VECs, the expression of IL-18 in CFs and DARC in VECs increased significantly, and using IL-18 RNAi on CFs can reduce the expression of DARC in VECs. In view of the role of CFs can inhibit angiogenesis, Our project team put forward the following hypothesis: CFs regulate VECs through IL-18 thus inhibiting angiogenesis. To test the hypothesis, we will build the expression and inhibiting adenovirus, and using immunofluorescence, western-blot, realtime-PCR, and FCM to clear the regulating effect and the signaling transduction mechanism of IL-18 to DARC in VECs. Then we will conduct further validation in vivo. The project will further revealed the regulating effect of CFs to angiogenesis, and it is expected to provide new drug targets and ideas for the treatment of surgery wound and angiogenesis related diseases.